The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Koji Harada

Department of Therapeutic Regulation for Oral Tumors

Institute of Health Biosciences

The University of Tokushima Graduate School

Tokushima 770-8504

Japan

[email]@*.tokushima-u.ac.jp

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Therapeutic Regulation for Oral Tumors, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima 770-8504, Japan. 2006 - 2008
  • Second Department of Oral and Maxillofacial Surgery, University of Tokushima, School of Dentistry, 3-18-15 Kuramoto, Japan. 2001 - 2005

References

  1. Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma. Harada, K., Sato, M., Ueyama, Y., Nagayama, M., Hamakawa, H., Nagahata, S., Yoshimura, Y., Osaki, T., Ryoke, K. Anticancer. Drugs (2008) [Pubmed]
  2. Investigation of optimal schedule of concurrent radiotherapy with S-1 for oral squamous cell carcinoma. Harada, K., Ferdous, T., Yoshida, H. Oncol. Rep. (2007) [Pubmed]
  3. S-1 inhibits tumorigenicity and angiogenesis of human oral squamous cell carcinoma cells by suppressing expression of phosphorylated Akt, vascular endothelial growth factor and fibroblast growth factor-2. Harada, K., Supriatno, , Kawashima, Y., Yoshida, H., Sato, M. Int. J. Oncol. (2007) [Pubmed]
  4. High expression of Jun activation domain-binding protein 1 (Jab1) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation. Harada, K., Kawashima, Y., Yoshida, H., Sato, M. Anticancer Res. (2006) [Pubmed]
  5. Thymidylate synthase expression in oral squamous cell carcinoma predicts response to S-1. Harada, K., Kawashima, Y., Yoshida, H., Sato, M. Oncol. Rep. (2006) [Pubmed]
  6. High antitumor activity using intratumoral injection of plasmid DNA with mutant-type p27Kip1 gene following in vivo electroporation. Harada, K., Supriatno, , Kawaguchi, S., Onoue, T., Kawashima, Y., Yoshida, H., Sato, M. Oncol. Rep. (2005) [Pubmed]
  7. Down-regulation of S-phase kinase associated protein 2 (Skp2) induces apoptosis in oral cancer cells. Harada, K., Supriatno, , Kawashima, Y., Itashiki, Y., Yoshida, H., Sato, M. Oral Oncol. (2005) [Pubmed]
  8. High expression of S-phase kinase-associated protein 2 (Skp2) is a strong prognostic marker in oral squamous cell carcinoma patients treated by UFT in combination with radiation. Harada, K., Supriatno, , Kawaguchi, S., Kawashima, Y., Itashiki, Y., Yoshida, H., Sato, M. Anticancer Res. (2005) [Pubmed]
  9. S-1, an oral fluoropyrimidine anti-cancer agent, enhanced radiosensitivity in a human oral cancer cell line in vivo and in vitro: involvement possibility of inhibition of survival signal, Akt/PKB. Harada, K., Kawaguchi, S., Supriatno, , Kawashima, Y., Yoshida, H., Sato, M. Cancer Lett. (2005) [Pubmed]
  10. Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8. Harada, K., Supriatno, , Yoshida, H., Sato, M. Int. J. Oncol. (2005) [Pubmed]
  11. Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Harada, K., Kawaguchi, S., Supriatno, , Onoue, T., Yoshida, H., Sato, M. Oral Oncol. (2004) [Pubmed]
  12. Overexpression of iNOS gene suppresses the tumorigenicity and metastasis of oral cancer cells. Harada, K., Supriatno, , Kawaguchi, S., Tomitaro, O., Yoshida, H., Sato, M. In. Vivo (2004) [Pubmed]
  13. Enhancement of apoptosis in salivary gland cancer cells by the combination of oral fluoropyrimidine anticancer agent (S-1) and radiation. Harada, K., Kawaguchi, S., Supriatno, , Onoue, T., Yoshida, H., Sato, M. Int. J. Oncol. (2004) [Pubmed]
  14. Cepharanthine exerts antitumor activity on oral squamous cell carcinoma cell lines by induction of p27Kip1. Harada, K., Supriatno, , Yamamoto, S., Kawaguchi, S., Yoshida, H., Sato, M. Anticancer Res. (2003) [Pubmed]
  15. Low p27Kip1 expression is associated with poor prognosis in oral squamous cell carcinoma. Harada, K., Supriatno, , Yoshida, H., Sato, M. Anticancer Res. (2002) [Pubmed]
  16. Characteristics of antitumour activity of cepharanthin against a human adenosquamous cell carcinoma cell line. Harada, K., Bando, T., Yoshida, H., Sato, M. Oral Oncol. (2001) [Pubmed]
 
WikiGenes - Universities